# NCT01948297 (NCT01948297)

> Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

No report yet. It can be ordered.

- Drugs tested: Debio 1347
- Indication: advanced solid tumors with FGFR alterations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01948297
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Debiopharm International SA
- Conditions: Solid Tumours
- Interventions: Debio1347 (CH5183284)
- Enrollment: 77
- Primary outcome: Part A: Percentage of Participants With Dose-Limiting Toxicities (DLTs) From Debio 1347
- Primary outcome: Part B: Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)
- Primary outcome: Part B: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
- Primary outcome: Part B: Severity of Treatment-Emergent AEs
- Primary outcome: Part B: Severity of Laboratory Abnormalities

## Indexed commentary on NCT01948297 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct01948297